183 related articles for article (PubMed ID: 34994578)
1. Role of the Immunohistochemical ZEB1 Expression in Uterine Mesenchymal Neoplasms.
Çelik M; Çelik ZE
Int J Surg Pathol; 2022 Aug; 30(5):520-527. PubMed ID: 34994578
[TBL] [Abstract][Full Text] [Related]
2. IFITM1 Outperforms CD10 in Differentiating Low-grade Endometrial Stromal Sarcomas From Smooth Muscle Neoplasms of the Uterus.
Busca A; Gulavita P; Parra-Herran C; Islam S
Int J Gynecol Pathol; 2018 Jul; 37(4):372-378. PubMed ID: 28700435
[TBL] [Abstract][Full Text] [Related]
3. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.
Croce S; Devouassoux-Shisheboran M; Pautier P; Ray-Coquard I; Treilleux I; Neuville A; Arnould L; Just PA; Belda MALF; Averous G; Leroux A; Mery E; Loussouarn D; Weinbreck N; Le Guellec S; Mishellany F; Morice P; Guyon F; Genestie C
Gynecol Oncol; 2022 Nov; 167(2):373-389. PubMed ID: 36114030
[TBL] [Abstract][Full Text] [Related]
4. [Mesenchymal and mixed uterine tumors : Current overview and practical aspects].
Lax SF
Pathologe; 2019 Feb; 40(1):36-45. PubMed ID: 30694356
[TBL] [Abstract][Full Text] [Related]
5. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype.
Oliva E; Clement PB; Young RH
Adv Anat Pathol; 2000 Sep; 7(5):257-81. PubMed ID: 10976906
[TBL] [Abstract][Full Text] [Related]
6. [Endometrial and other rare uterine sarcomas : Diagnostic aspects in the context of the 2020 WHO classification].
Mayr D; Horn LC; Hiller GGR; Höhn AK; Schmoeckel E
Pathologe; 2022 May; 43(3):183-195. PubMed ID: 35362728
[TBL] [Abstract][Full Text] [Related]
7. Endometrial stromal sarcomas with unusual histologic features: a report of 24 primary and metastatic tumors emphasizing fibroblastic and smooth muscle differentiation.
Yilmaz A; Rush DS; Soslow RA
Am J Surg Pathol; 2002 Sep; 26(9):1142-50. PubMed ID: 12218570
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new.
Hwang H; Matsuo K; Duncan K; Pakzamir E; Pham HQ; Correa A; Fedenko A; Mhawech-Fauceglia P
J Clin Pathol; 2015 Sep; 68(9):710-7. PubMed ID: 25991737
[TBL] [Abstract][Full Text] [Related]
9. Cellular mesenchymal tumors of the uterus: a review emphasizing recent observations.
Oliva E
Int J Gynecol Pathol; 2014 Jul; 33(4):374-84. PubMed ID: 24901397
[TBL] [Abstract][Full Text] [Related]
10. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors.
Nucci MR; O'Connell JT; Huettner PC; Cviko A; Sun D; Quade BJ
Am J Surg Pathol; 2001 Apr; 25(4):455-63. PubMed ID: 11257619
[TBL] [Abstract][Full Text] [Related]
11. Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma.
Loddenkemper C; Mechsner S; Foss HD; Dallenbach FE; Anagnostopoulos I; Ebert AD; Stein H
Am J Surg Pathol; 2003 Nov; 27(11):1458-62. PubMed ID: 14576480
[TBL] [Abstract][Full Text] [Related]
12. Uterine sarcomas.
Mbatani N; Olawaiye AB; Prat J
Int J Gynaecol Obstet; 2018 Oct; 143 Suppl 2():51-58. PubMed ID: 30306577
[TBL] [Abstract][Full Text] [Related]
13. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus.
Wang L; Felix JC; Lee JL; Tan PY; Tourgeman DE; O'Meara AT; Amezcua CA
Gynecol Oncol; 2003 Aug; 90(2):402-6. PubMed ID: 12893208
[TBL] [Abstract][Full Text] [Related]
14. Recurrent KAT6B/A::KANSL1 Fusions Characterize a Potentially Aggressive Uterine Sarcoma Morphologically Overlapping With Low-grade Endometrial Stromal Sarcoma.
Agaimy A; Clarke BA; Kolin DL; Lee CH; Lee JC; McCluggage WG; Pöschke P; Stoehr R; Swanson D; Turashvili G; Beckmann MW; Hartmann A; Antonescu CR; Dickson BC
Am J Surg Pathol; 2022 Sep; 46(9):1298-1308. PubMed ID: 35575789
[TBL] [Abstract][Full Text] [Related]
15. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms.
McCluggage WG; Sumathi VP; Maxwell P
Histopathology; 2001 Sep; 39(3):273-8. PubMed ID: 11532038
[TBL] [Abstract][Full Text] [Related]
16. [Sarcomas and mixed mesodermal tumors of the uterus].
Günthert AR
Ther Umsch; 2011 Oct; 68(10):559-64. PubMed ID: 21968895
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours].
Croce S; Devouassoux-Shisheboran M; Pautier P; Ray-Coquard I; Treilleux I; Neuville A; Arnould L; Just PA; Le Frere Belda MA; Averous G; Leroux A; Bataillon G; Mery E; Loussouarn D; Weinbreck N; Le Guellec S; Mishellany F; Morice P; Guyon F; Genestie C
Bull Cancer; 2024 Jan; 111(1):97-116. PubMed ID: 37806863
[TBL] [Abstract][Full Text] [Related]
18. SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study.
Le Page C; Almadani N; Turashvili G; Bataillon G; Portelance L; Provencher D; Mes-Masson AM; Gilks B; Hoang L; Rahimi K
Int J Gynecol Pathol; 2021 Sep; 40(5):487-494. PubMed ID: 33720083
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatment in adult uterine sarcomas.
Desar IME; Ottevanger PB; Benson C; van der Graaf WTA
Crit Rev Oncol Hematol; 2018 Feb; 122():10-20. PubMed ID: 29458779
[TBL] [Abstract][Full Text] [Related]
20. Update on Uterine Mesenchymal Neoplasms.
Kertowidjojo EC; Bennett JA
Surg Pathol Clin; 2022 Jun; 15(2):315-340. PubMed ID: 35715164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
